Long-term checkup for Miltenyi cell therapy patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Skin clinical trials.
This study is a long-term check-in for people who received a special type of immunotherapy (CAR T cells) made by Miltenyi. It helps researchers see how you're doing over time after your treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received treatment with a Miltenyi CAR T cell therapy in a previous study.
- At least 12 months have passed since you got that treatment.
- You agree to take part in this long-term follow-up and give your consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
This study is a long-term follow-up for people who previously received a gene therapy treatment called zamtocabtagene autoleucel in a Miltenyi Biomedicine-sponsored clinical study. It helps researchers monitor your health over time after the treatment.
Hear when a new Melanoma Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.